Cabozantinib (Cabometyx) for Hepatocellular Carcinoma - Details


( Last Updated : May 7, 2020)
Generic Name:
Cabozantinib
Project Status:
Complete
Therapeutic Area:
HCC
Manufacturer:
Ipsen Biopharmaceuticals Canada Inc.
Brand Name:
Cabometyx
Project Line:
Reimbursement Review
Project Number:
PC0186-000
NOC Status at Filing:
Pre NOC
NOC Date:

Details


Strength:
20 mg, 40 mg & 60 mg
Tumour Type:
Gastrointestinal
Indications:
Hepatocellular Carcinoma
Funding Request:
For the treatment of Hepatocellular Carcinoma (HCC) in adults after prior therapy
Pre Noc Submission:
Yes
Sponsor:
Ipsen Biopharmaceuticals Canada Inc.
Submission Date:
Submission Deemed Complete:
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
pERC Meeting:
Final Recommendation Issued:

Files

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.